Novo Nordisk
Sign up for E-mail Notification Search Site:   Search Site
Home Professional Site Patient Resources Glossary References Prescribing Information
Hemophilia With Inhibitors Factor VII Deficiency Acquired Hemophilia Surgery Information About NovoSeven Recombinant Safety SevenSECURE
Bookmark Print Page E-mail a Friend
Patient Resources
Inhibitor Patient Education Summits
Community Talks on Rare Bleeding Disorders
Relevant Associations
Inhibitor Patient Education Summits Back
www.inhibitorsummits.org
What is an Inhibitor Patient Education Summit? In short, an educational opportunity—just for patients with inhibitors and their caregivers.
The Inhibitor Patient Education Summits are meetings focused on topics of interest for patients who have or once had inhibitors. Their caregivers are also invited to attend. The speakers and agendas for these meetings have been put together under the direction of the steering committee of national and local hemophilia leaders, including physicians, nurses, advocates, patients, and representatives from physical therapy and social work.
Last year the first Summit was held in Philadelphia, which was a great success. More than 50 families came together with hemophilia leaders for a weekend of learning, sharing, and networking experience. There were general sessions that addressed universal topics of interest, as well as smaller, more informal sessions where specific topics were discussed by patients and hemophilia leaders. Those who attended the meeting gained much more than new insights into treating and living with an inhibitor—they created personal and professional connections that will continue to teach, support, and inspire.
The Summit program is funded by Novo Nordisk and does not give preference to any particular treatment.
For more information, or to see the schedule and agenda, click here.
Community Talks on Rare Bleeding Disorders Back
Treatment of rare bleeding disorders has come a long way in the past decade. With so many advancements in knowledge and care, it can be difficult to stay well informed.
Now you can get access to the latest information through the Community Talks on Rare Bleeding Disorders program. Sponsored by Novo Nordisk and presented by well-respected hemophilia healthcare providers within the bleeding disorder community, these talks promise to be very engaging and educational events. If you are interested in attending a Community Talk near you, please call 1-877-NOVO-777 (1-877-668-6777) for more information.
Relevant Associations Back
National Hemophilia Foundation (NHF)
www.hemophilia.org
The NHF is dedicated to finding better treatments and cures for bleeding and clotting disorders and to preventing the complications of these disorders through education, advocacy, and research. Visit their Web site for more information or to locate a chapter near you.
Hemophilia Federation of America (HFA)
www.hemophiliafed.org
The HFA is a national 501(c)(3) with a mission of assistance, education, and advocating for the hemophilia community. It administers programs that address the needs of patients and their families. It also serves as a unique network of support for the community by the community.
World Federation of Hemophilia (WFH)
www.wfh.org
An extensive Web site with information about international developments in the advancement of hemophilia care.
American Society of Pediatric Hematology/Oncology (ASPH/O)
www.aspho.org
The Society serves both medical professionals and patients. It is dedicated to advancing knowledge in pediatric blood diseases and cancer.
Centers for Disease Control and Prevention (CDC)
www.cdc.gov
An agency of the US Department of Health and Human Services (HHS), the CDC focuses on preventing and controlling disease, injury, and disability.

IMPORTANT SAFETY INFORMATION

NovoSeven® was studied in 298 patients with hemophilia A or B with inhibitors treated for 1939 bleeding episodes.

  • The most common side effects in people taking NovoSeven were fever, bleeding, a decrease in the amount of coagulation factor 1, pain from blood collecting in a joint, and high blood pressure
  • People who have ever had a bad reaction to proteins from mice, hamsters, or "bovines" (such as an ox or cow) should not be treated with NovoSeven
  • After taking NovoSeven, some patients have more of a risk of thrombosis, which is when a clot forms in a blood vessel and causes harm. Although the extent of this risk is not known, it is thought to be small. Some patients have conditions that may increase this risk. These include clogged arteries, blood clots that form throughout the body instead of at the place of injury, a type of blood poisoning called septicemia, and crush injury, which is when a body part is crushed or squeezed between heavy or immobile objects. Also, people taking aPCCs/PCCs (activated or nonactivated prothrombin complex concentrates) at the same time that they're taking NovoSeven may be at increased risk for thrombosis.
  • Serious adverse events which may or may not have been related to the use of NovoSeven occurred in 14 of the 298 patients in the initial clinical program. Please see the enclosed prescribing information.
  • There have been no reports of NovoSeven causing bad reactions to "analgesics" (such as pain killers), "antibiotics" (the drugs used to treat infection), or "sedatives" (sleeping pills or tranquillizers).
  • Development of antibodies against Factor VII have been reported in Factor VII deficient patients after treatment with NovoSeven. These patients had previously been treated with human plasma and/or plasma-derived factor VII.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
NovoSeven is a registered trademark of Novo Nordisk Health Care AG.
© 2008 Novo Nordisk Inc. All Rights Reserved 130601R1 June 2008
Privacy Policy Legal Statement Site Map Contact Us
Hemophilia With Inhibitors Factor VII Deficiency Surgery Information About NovoSeven Recombinant Safety SevenSECURE